Telix Pharmaceuticals Ltd (ASX:TLX) is adding to its portfolio of early-stage drug candidates, in addition to a suite of other assets, through a $73 million asset buy agreement with antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback